Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Takeda Pharmaceutical Company Limited is a drug manufacturers-specialty & generic business based in the US. Takeda Pharmaceutical Company shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Takeda Pharmaceutical Company employs 47,099 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $14.66 |
|---|---|
| 52-week range | $13.17 - $19.97 |
| 50-day moving average | $13.88 |
| 200-day moving average | $15.84 |
| Wall St. target price | $17.76 |
| PE ratio | 11.2811 |
| Dividend yield | $180 (5.52%) |
| Earnings per share (TTM) | $1.31 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $14.66 from 2022-01-21
| 1 week (2022-01-14) | -0.61% |
|---|---|
| 1 month (2021-12-23) | 6.46% |
| 3 months (2021-10-22) | 4.19% |
| 6 months (2021-07-23) | -13.05% |
| 1 year (2021-01-22) | -19.14% |
|---|---|
| 2 years (2020-01-23) | -26.77% |
| 3 years (2019-01-23) | 19.95 |
| 5 years (2017-01-23) | 20.94 |
Valuing Takeda Pharmaceutical Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Takeda Pharmaceutical Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Takeda Pharmaceutical Company shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Takeda Pharmaceutical Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.952. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Takeda Pharmaceutical Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1,065.2 billion.
The EBITDA is a measure of a Takeda Pharmaceutical Company's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $3,401.4 billion |
|---|---|
| Operating margin TTM | 16.73% |
| Gross profit TTM | $2,203.6 billion |
| Return on assets TTM | 2.85% |
| Return on equity TTM | 9.48% |
| Profit margin | 13.91% |
| Book value | $1,692.47 |
| Market capitalisation | $46.5 billion |
TTM: trailing 12 months
Dividend payout ratio: 57.37% of net profits
Recently Takeda Pharmaceutical Company has paid out, on average, around 57.37% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.52% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Takeda Pharmaceutical Company shareholders could enjoy a 5.52% return on their shares, in the form of dividend payments. In Takeda Pharmaceutical Company's case, that would currently equate to about $180 per share.
Takeda Pharmaceutical Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Takeda Pharmaceutical Company's most recent dividend payout was on 14 December 2009. The latest dividend was paid out to all shareholders who bought their shares by 28 September 2021 (the "ex-dividend date").
Over the last 12 months, Takeda Pharmaceutical Company's shares have ranged in value from as little as $13.17 up to $19.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Takeda Pharmaceutical Company's is 1.086. This would suggest that Takeda Pharmaceutical Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc. , and Arrowhead Pharmaceuticals Inc. ; research collaboration agreements with Arrowhead Pharmaceuticals Inc.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
